Download: Daratumumab, a novel therapeutic human CD38 monoclonal antibody – a promising new treatment option in multiple myeloma

MKB

Download this presentation here >

The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds.

At the 2013 event, delegates were fortunate enough to hear from Dr Michael Karl Bauer, Senior Vice President of Clinical Development, Genmab, who delivered the presentation ‘Daratumumab, a novel therapeutic human CD38 monoclonal antibody – a promising new treatment option in multiple myeloma‘.

Download this presentation here >

If you’re interested in in learning more and engaging in discussion on mAbs, ADC’s, bispecifics and antibody biosimilars, you might want to check out the European Antibody Congress 2014 – preparations are in full swing! Make sure you’re networking with senior executives and opinion leaders across the antibody space.

Leave a Reply

Your email address will not be published. Required fields are marked *